CCEL on NYSE
CRYO CELL INTERNATIONAL INC
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Marpai, Inc., PACIFIC HEALTH CARE ORGANIZATION INC or Charming Medical Ltd, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Processing And Storage Fees brought in 99% of the revenue CRYO CELL INTERNATIONAL INC broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Processing And Storage Fees | $31.6M | $31.4M |
| Public Banking | $366.7K | $129.5K |
| Product | $67.9K | $54.1K |
Business segments
Umbilical Cord Blood And Cord Tissue Stem Cell Service brought in 99% of the revenue CRYO CELL INTERNATIONAL INC broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Umbilical Cord Blood And Cord Tissue Stem Cell Service | $31.6M | $31.4M |
| Public Cord Blood Banking | $366.7K | $129.5K |
| Prepacytecb | $67.9K | $54.1K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue23¢$7.4M
- Research and development1¢$376.3K
- Selling, general and admin58¢$18.2M
- Other costs11¢$3.4M
- Interest7¢$2.1M
- Income tax0¢$92.2K
Out of $31.6M in revenue.3 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending4¢$230.5K
- Dividends paid59¢$3.2M
- Share buybacks3¢$169.5K
- Kept or used elsewhere34¢$1.8M
Out of $5.5M of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-11-30 | 2024-11-30 |
|---|---|---|
| Revenue | $31.6M | $32.0M |
| Cost of sales | $7.4M | $7.9M |
| Selling, general and administrative expenses | $18.2M | $18.5M |
| Impairment of public inventory | $4.4M | $0 |
| Research, development and related engineering | $376.3K | $1.2M |
| Depreciation and amortization | $751.5K | $483.5K |
| Total costs and expenses | $31.1M | $28.5M |
| Operating Income | $482.4K | $3.5M |
| (Losses) gains on marketable securities | -$806.3K | $1.1M |
| Gain on interest rate swap | $0 | $105.9K |
| Other income | $53.0K | $6.6K |
| Interest expense | -$2.1M | -$1.9M |
| Total other (expense) income | -$2.8M | -$676.2K |
| (Loss) income before income tax expense | -$2.3M | $2.8M |
| Income tax expense | -$92.2K | -$2.4M |
| Net (loss) income | -$2.4M | $402.1K |
| Net (loss) income per common share - basic | -$0.30 | $0.05 |
| Weighted average common shares outstanding - basic | 8.1M shares | 8.1M shares |
| Net (loss) income per common share - diluted | -$0.30 | $0.05 |
| Weighted average common shares outstanding - diluted | 8.1M shares | 8.2M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-11-30 | 2024-11-30 | 2023-11-30 |
|---|---|---|---|
| Cash and cash equivalents | $319.0K | $561.0K | |
| Marketable securities | $3.0M | $2.9M | |
| Accounts receivable (net of allowance for doubtful accounts of $4,306,410 and $4,266,405, respectively) | $6.8M | $7.3M | $6.6M |
| Prepaid expenses | $573.2K | $637.1K | |
| Inventory, current portion | $408.8K | $657.7K | |
| Other current assets | $634.0K | $454.6K | |
| Total current assets | $11.8M | $12.6M | |
| Property and Equipment-net | $21.0M | $21.9M | |
| Intangible assets, net | $863.1K | $921.3K | |
| Inventory, net of current portion | $776.0K | $4.9M | |
| Goodwill | $1.9M | $1.9M | |
| Deferred tax assets | $23.6M | $20.8M | |
| Operating lease right-of-use asset | $819.6K | $806.3K | |
| Deposits and other assets, net | $915.1K | $815.6K | |
| Total other assets | $28.9M | $30.2M | |
| Total assets | $61.7M | $64.7M | |
| Accounts payable | $2.9M | $1.9M | |
| Accrued expenses | $4.3M | $5.8M | |
| Note payable | $183.7K | $170.5K | |
| Line of credit | $2.3M | $3.5M | |
| Current portion of operating lease liability | $430.2K | $428.3K | |
| Deferred revenue | $9.7M | $9.8M | |
| Total current liabilities | $19.8M | $21.6M | |
| Deferred revenue, net of current portion | $51.0M | $46.6M | |
| Note payable, net of current portion and debt issuance costs | $8.2M | $8.3M | |
| Operating lease long-term liability | $474.6K | $505.1K | |
| Long-term liability - revenue sharing agreements | $875.0K | $875.0K | |
| Other liabilities | $47.0K | $47.0K | |
| Total other liabilities | $60.5M | $56.3M | |
| Total liabilities | $80.3M | $77.9M | |
| Commitments and contingencies (Note 12) | $0 | $0 | |
| Preferred stock | $0 | $0 | |
| Common stock ($.01 par value, 20,000,000 authorized; 14,877,119 issued and 8,055,150 outstanding as of November 30, 2025 and 14,869,619 issued and 8,082,159 outstanding as of November 30, 2024) | $148.8K | $148.7K | |
| Additional paid-in capital | $44.7M | $44.3M | |
| Treasury stock, at cost | -$25.0M | -$24.9M | |
| Accumulated deficit | -$38.4M | -$32.8M | |
| Total stockholders' deficit | -$18.6M | -$13.2M | -$11.0M |
| Total liabilities and stockholders' deficit | $61.7M | $64.7M | |
| Accounts receivable, allowance for doubtful accounts | $4.3M | $4.3M | $3.8M |
| Preferred stock, par value | $0.01 | $0.01 | |
| Preferred stock, shares authorized | 500.0K shares | 500.0K shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.01 | $0.01 | |
| Common stock, shares authorized | 20.0M shares | 20.0M shares | |
| Common stock, shares issued | 14.9M shares | 14.9M shares | |
| Common stock, shares outstanding | 8.1M shares | 8.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-11-30 | 2024-11-30 | 2023-11-30 |
|---|---|---|---|
| Net (loss) income | -$2.4M | $402.1K | |
| Depreciation and amortization expense | $985.2K | $693.8K | |
| Impairment of public inventory | $4.4M | $0 | |
| Impairment of investment - Tianhe stock | $0 | $308.0K | |
| Loss on sale of property and equipment | $48.3K | $0 | |
| Losses (gains) on marketable securities | $806.3K | -$1.1M | |
| Unrealized gain on interest rate swap contract | $0 | -$105.9K | |
| Compensatory element of stock options | $417.1K | $781.1K | |
| Provision for doubtful accounts | $868.8K | $1.3M | $868.8K |
| Deferred income tax benefit | -$2.8M | -$309.3K | |
| Amortization of debt issuance costs | $20.8K | $21.2K | |
| Amortization of operating lease right-of-use asset | $382.9K | $327.8K | |
| Accounts receivable | -$405.9K | -$2.0M | |
| Prepaid expenses | $63.8K | -$21.6K | |
| Inventory | $56.2K | $429.2K | |
| Other current assets | -$179.4K | -$64.6K | |
| Deposits and other assets, net | -$99.5K | -$69.1K | |
| Accounts payable | $1.0M | -$423.7K | |
| Accrued expenses | -$1.5M | $639.1K | |
| Operating lease liability | -$424.7K | -$245.2K | |
| Other liabilities | $0 | $2.8K | |
| Deferred revenue | $4.4M | $5.5M | |
| Net cash from operating activities | $5.5M | $6.0M | |
| Purchases of property and equipment | -$230.5K | -$2.4M | |
| Sale of property and equipment | $115.0K | $0 | |
| Payment of Duke license agreement | $0 | -$1.2M | |
| Proceeds from liquidation of marketable securities | $0 | $101.9K | |
| Purchases of marketable securities | -$3.6M | -$2.9M | |
| Sale of marketable securities | $2.8M | $1.5M | |
| Net cash used in investing activities | -$975.3K | -$4.9M | |
| Treasury stock purchases | -$169.5K | -$1.4M | |
| Repayments of note payable | -$147.6K | -$136.4K | |
| Repayment of line of credit | -$10.0M | -$2.9M | |
| Proceeds from the exercise of stock options | $23.1K | $76.4K | |
| Proceeds from line of credit | $8.8M | $5.2M | |
| Dividends paid | -$3.2M | -$2.0M | |
| Proceeds from Swap termination | $0 | $228.0K | |
| Net cash used in financing activities | -$4.7M | -$979.1K | |
| (Decrease) increase in cash and cash equivalents | -$241.9K | $154.9K | |
| Lease liability arising from right-of-use asset | $396.2K | $100.9K | |
| Construction costs payable | $0 | -$880.3K | |
| Interest | $2.0M | $2.0M | |
| Income taxes | $4.6M | $2.7M |
Recent filings
- Oct 13, 2026ARS
- Oct 13, 2026DEF 14A
- Oct 9, 202610-Q
- Sep 14, 20268-K
- Aug 7, 20264
- Jul 15, 202610-Q
- Jul 7, 2026SCHEDULE 13D/A
- May 29, 20264
- May 8, 20268-K
- Apr 14, 202610-Q
- Mar 25, 2026SCHEDULE 13D
- Mar 12, 20268-K
- Feb 27, 202610-K
- Jan 9, 20264
- Jan 9, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11